FDA-approved medication use for all individuals with SCD and those with an average of 2 or more pain episodes in every 12-month period
| Medication . | All individuals with SCD . | Individuals with SCD and 2 or more pain episodes in a year . |
|---|---|---|
| Hydroxyurea | 24.6% (n = 1957/7957) | 31.5% (n = 1428/4531) |
| L-glutamine | 2.0% (n = 149/7345) | 3.2% (n = 135/4191) |
| Voxelotor | 1.9% (n = 101/5304) | 2.9% (n = 85/2888) |
| Crizanlizumab | 1.4% (n = 72/5304) | 2.3% (n = 65/2888) |
| Hydroxyurea + L-glutamine | 1.2% (n = 86/7345) | 1.8% (n = 76/4191) |
| Hydroxyurea + Voxelotor | 1.0%(n = 55/5304) | 1.6% (n = 46/2888) |
| Hydroxyurea + crizanlizumab | 0.6% (n = 34/5304) | 1.1% (n = 33/2888) |
| Crizanlizumab + L-glutamine | 0.1% (n = 5/5304) | 0.2% (n = 5/2888) |
| Hydroxyurea + L-glutamine + crizanlizumab | <0.1% (n = 3/5304) | 0.1% (n = 3/2888) |
| Medication . | All individuals with SCD . | Individuals with SCD and 2 or more pain episodes in a year . |
|---|---|---|
| Hydroxyurea | 24.6% (n = 1957/7957) | 31.5% (n = 1428/4531) |
| L-glutamine | 2.0% (n = 149/7345) | 3.2% (n = 135/4191) |
| Voxelotor | 1.9% (n = 101/5304) | 2.9% (n = 85/2888) |
| Crizanlizumab | 1.4% (n = 72/5304) | 2.3% (n = 65/2888) |
| Hydroxyurea + L-glutamine | 1.2% (n = 86/7345) | 1.8% (n = 76/4191) |
| Hydroxyurea + Voxelotor | 1.0%(n = 55/5304) | 1.6% (n = 46/2888) |
| Hydroxyurea + crizanlizumab | 0.6% (n = 34/5304) | 1.1% (n = 33/2888) |
| Crizanlizumab + L-glutamine | 0.1% (n = 5/5304) | 0.2% (n = 5/2888) |
| Hydroxyurea + L-glutamine + crizanlizumab | <0.1% (n = 3/5304) | 0.1% (n = 3/2888) |
Denominators are based on eligible participants when medications were approved by the FDA.